← Eichor
Study identifier: NCT05046613 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

Condition: Migraine  ·  Sponsor: Pfizer

PhaseN/A
Planned participants780
Who can joinFemale, 0 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.

This description comes directly from the study's public registry record.

Talk to the study team

Pfizer Pfizer CT.gov Call Center  ·  1-800-718-1021  ·  ClinicalTrials.gov_Inquiries@pfizer.com

Always discuss trial participation with your own doctor first.

Locations (1)

Evidera, a PPD business unitWilmington, North Carolina, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05046613